RSV Vaccines

About

RSV vaccines are designed to protect against Respiratory Syncytial Virus, a common cause of severe respiratory illness in vulnerable populations, such as infants and older adults. These vaccines work by stimulating the immune system to produce antibodies that recognize and combat RSV, thereby reducing the risk of severe complications like pneumonia and bronchiolitis. Available vaccines include protein-based options like AREXVY and ABRYSVO, which are recommended for adults aged 60 and older, and an mRNA-based vaccine, mRESVIA, also for older adults. For infants, protection is achieved through maternal vaccination during pregnancy or the administration of monoclonal antibodies like nirsevimab. Maternal vaccination involves a single dose given between weeks 32-36 of gestation, providing newborns with antibodies against RSV. Monoclonal antibodies offer immediate protection and are particularly beneficial for high-risk infants. RSV vaccines not only protect individuals but also help reduce the spread of the virus within communities, which is crucial for safeguarding those at higher risk of severe illness. By preventing severe RSV infections, these vaccines contribute significantly to public health by reducing hospitalizations and deaths associated with the virus.